NCT07520305尚未招募不适用
A Study of the Efficacy Heterogeneity of Lactobacillus Paracasei LC19 Intervention in Patients With Newly Diagnosed Type 2 Diabetes
Beijing Chao Yang Hospital1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2026年4月20日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- HbA1c change
研究概览
简要总结
This is a single-arm study to investigate the heterogeneity of glycemic response to Lactobacillus paracasei LC19 in patients with newly diagnosed type 2 diabetes. Participants will receive LC19 for 12 weeks, and changes in glycemic control will be evaluated.
详细描述
This is a single-center, open-label, single-arm study designed to investigate inter-individual variability in glycemic response to Lactobacillus paracasei LC19 (LC19) in patients with newly diagnosed type 2 diabetes (T2D). A total of 70 eligible participants with newly diagnosed T2DM will be enrolled. All participants will receive oral LC19 strain powder (2 packets per day, 2 g per packet) for 12 weeks. No placebo or active comparator will be included in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-65 years, both genders eligible
- •Drug-naive patients with newly diagnosed type 2 diabetes
- •Subjects with screening HbA1c ≥ 7.0% and ≤ 9.0%
- •Subjects understand the nature, significance, potential benefits, inconvenience, and risks and procedure of the study, and voluntarily sign the informed consent form
排除标准
- •Other types of diabetes except T2D: type 1 diabetes (including adult latent autoimmune diabetes), special type diabetes, or secondary diabetes (such as acromegaly or Cushing's syndrome, etc.)
- •Subjects with acute diabetic complications such as diabetic ketoacidosis or diabetic hyperosmolar coma in the past 6 months
- •Subjects with history of hypoglycemia in the past 6 months
- •Subjects with history of New York Heart Association class (NYHA) grade of heart function ≥ III or serious cardiovascular diseases (myocardial infarction, or with the history of cardiac interventional therapy or stent implantation, valve disease or valve repair, unstable angina, transient ischemic attack or stroke) within 6 months before the screening period
- •Subjects with history of chronic active hepatitis and/or severe liver dysfunction, renal dysfunction, and thyroid dysfunction
- •Subjects with a medical history of malignant tumor
- •Subjects with history of gastrointestinal diseases that affect food digestion and absorption (such as severe diarrhea, constipation, irritable bowel syndrome, inflammatory bowel disease, active gastrointestinal ulcers, acute cholecystitis, etc.) or with a history of intestinal resection or other gastrointestinal surgery (such as cholecystectomy) within one year before the screening period
- •Subjects with history of surgery, or severe trauma in the past 6 months, or planning to undergo surgery during the study period
- •Subjects suffering from severe infections, severe anemia, or neutropenia
- •Subjects pregnant or in lactation, or those planning to become pregnant or impregnate during or within 3 months after the study period
- •Subjects with history of receiving immunosuppressants, steroids, anti diarrheal drugs, antibiotics, lipid-lowering drugs, or other gastrointestinal motility medications within the past 3 months
- •Subjects using other medications that can affect blood glucose in the past 3 months
- •Subjects with consumption of other probiotic or prebiotic products in the past 3 months before secreening
- •Subjects with lactose intolerance, known or suspected allergy to probiotics used in experiments, history of drug allergies or allergic diseases
- •Subjects with weight fluctuations ≥ 5kg in the past 3 months or planning to take medication to control weight during the study period
- •Subjects with history of mental illness or epilepsy, or taking antidepressant medications
- •Subjects with history of alcohol abuse (for men, alcohol consumption exceeding 40 grams per day and for women, exceeding 20 grams per day)
- •Subjects have participated in any other clinical study in the past 3 months
研究组 & 干预措施
Lactobacillus paracasei LC19 supplementation
Experimental
All participants will receive oral Lactobacillus paracasei LC19 powder (2g/packet, 2 packets/day) for 12 weeks.
干预措施: Lactobacillus paracasei LC19 Intervention (Dietary Supplement)
结局指标
主要结局
HbA1c change
时间窗: 12 weeks
Changes in HbA1c from baseline to week 12 during follow-up
次要结局
- BMI change(12 weeks)
- Glucose tolerance(12 weeks)
- Plasma GLP-1 change(12 weeks)
- Weight change(12 weeks)
- Alteration of gut microbiome(12 weeks)
研究者
Guang Wang
Chief Physician
Beijing Chao Yang Hospital
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Clinical efficacy of lactobacillus salivarus probiotic gel and chlorhexidine gel along with scaling and root planing.CTRI/2025/09/094730Golapala Naga Aishwarya48
已完成
1 期
Evaluating the capacity of probiotic chewable tablets containing probiotic bacteria on halitosis enzyme levels in patients with bad breath as an adjunct totooth cleaning –a randomized control trial study.CTRI/2025/03/082544Lakshmi C40
Unknown
不适用
格氏乳杆菌对 1 型糖尿病的临床辅助疗效评价：多中心、随机双盲、对照临床研究ChiCTR2400087049国家自然科学基金（82122068）
Unknown
不适用
双歧杆菌（R0033，R0071）联合干预对不同 LCT 基因型乳糖不耐受婴儿肠道菌群和临床结局影响的随机对照研究ChiCTR2300067481中国疾病预防控制中心妇幼保健中心
招募中
不适用
Effect of use of Lactobacillus plantarum UBLP-40 in addition iron supplement on anemia in pregnant womenCTRI/2024/09/073839Unique Biotech240